{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:13:19Z","timestamp":1791511999750,"version":"4.3.4"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The combination of fluconazole (FLC) and cyclosporine (CY) is fungicidal in FLC-susceptible\n            <jats:italic>C. albicans<\/jats:italic>\n            (O. Marchetti, P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard, Antimicrob. Agents Chemother. 44:2373-2381, 2000). The mechanism of this synergism is unknown. CY has several cellular targets including multidrug efflux transporters. The hypothesis that CY might inhibit FLC efflux was investigated by comparing the effect of FLC-CY in FLC-susceptible parent CAF2-1 (FLC MIC, 0.25 mg\/liter) and in FLC-hypersusceptible mutant DSY1024 (FLC MIC, 0.03 mg\/liter), in which the\n            <jats:italic>CDR1<\/jats:italic>\n            ,\n            <jats:italic>CDR2<\/jats:italic>\n            ,\n            <jats:italic>CaMDR1<\/jats:italic>\n            , and\n            <jats:italic>FLU1<\/jats:italic>\n            transporter genes have been selectively deleted. We postulated that a loss of the fungicidal effect of FLC-CY in DSY1024 would confirm the roles of these efflux pumps. Time-kill curve studies showed a more potent fungistatic effect of FLC (\n            <jats:italic>P<\/jats:italic>\n            = 0.05 at 48 h with an inoculum of 10\n            <jats:sup>3<\/jats:sup>\n            CFU\/ml) and a more rapid fungicidal effect of FLC-CY (\n            <jats:italic>P<\/jats:italic>\n            = 0.05 at 24 h with an inoculum of 10\n            <jats:sup>3<\/jats:sup>\n            CFU\/ml) in the FLC-hypersusceptible mutant compared to those in the parent. Rats with experimental endocarditis were treated for 2 or 5 days with high-dose FLC, high-dose CY, or both drugs combined. FLC monotherapy for 5 days was more effective against the hypersusceptible mutant than against the parent. However, the addition of CY to FLC still conferred a therapeutic advantage in animals infected with mutant DSY1024, as indicated by better survival (\n            <jats:italic>P<\/jats:italic>\n            = 0.04 versus the results obtained with FLC) and sterilization of valves and kidneys after a very short (2-day) treatment (\n            <jats:italic>P<\/jats:italic>\n            = 0.009 and 0.002, respectively, versus the results obtained with FLC). Both in vitro and in vivo experiments consistently showed that the deletion of the four membrane transporters in DSY1024 did not result in loss of the fungicidal effect of FLC-CY. Yet, the accelerated killing in the mutant suggested a \u201cdual-hit\u201d mechanism involving FLC hypersusceptibility due to the efflux pump elimination and fungicidal activity conferred by CY. Thus, inhibition of multidrug efflux transporters encoded by\n            <jats:italic>CDR1<\/jats:italic>\n            ,\n            <jats:italic>CDR2<\/jats:italic>\n            ,\n            <jats:italic>CaMDR1<\/jats:italic>\n            , and\n            <jats:italic>FLU1<\/jats:italic>\n            genes is not responsible for the fungicidal synergism of FLC-CY. Other cellular targets must be considered.\n          <\/jats:p>","DOI":"10.1128\/aac.47.5.1565-1570.2003","type":"journal-article","created":{"date-parts":[[2003,4,22]],"date-time":"2003-04-22T21:03:23Z","timestamp":1051045403000},"page":"1565-1570","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["Fungicidal Synergism of Fluconazole and Cyclosporine in\n            <i>Candida albicans<\/i>\n            Is Not Dependent on Multidrug Efflux Transporters Encoded by the\n            <i>CDR1<\/i>\n            ,\n            <i>CDR2<\/i>\n            ,\n            <i>CaMDR1<\/i>\n            , and\n            <i>FLU1<\/i>\n            Genes"],"prefix":"10.1128","volume":"47","author":[{"given":"Oscar","family":"Marchetti","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreillon","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0300 M.","family":"Entenza","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Vouillamoz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P.","family":"Glauser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bille","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Sanglard","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/513663"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1247"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-146-11-2743"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.263"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/21.1.1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/134.3.717"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0165-2478(85)90118-X","volume":"11","year":"1985","unstructured":"Haynes, M., L. Fuller, D. H. Haynes, and J. Miller. 1985. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture. Immunol. Lett.11:343-349.","journal-title":"Immunol. Lett."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.37.1.127-131.1982"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.0140"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.1993.11.9.1652","volume":"11","year":"1993","unstructured":"List, A. F., C. Spier, J. Greer, S. Wolff, J. Hutter, R. Dorr, S. Salmon, B. Futscher, M. Baier, and W. Dalton. 1993. Phase I\/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol.11:1652-1660.","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2932-2938.2000"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.696-700.2001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2373-2381.2000"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1152\/physrev.1996.76.3.631","volume":"76","year":"1996","unstructured":"Marks, A. R. 1996. Cellular functions of immunophilins. Physiol. Rev.76:631-649.","journal-title":"Physiol. Rev."},{"key":"e_1_3_2_16_2","unstructured":"McGinnis M. R. and M. G. Rinaldi. 1996. Antifungal drugs: mechanisms of action drug resistance susceptibility testing and assays of activity in biologic fluids p. 176-211. In V. Lorian (ed.) Antibiotics in laboratory medicine. The Williams & Wilkins Co. Baltimore Md."},{"key":"e_1_3_2_17_2","unstructured":"National Committee for Clinical and Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts vol. 17 no. 9. Approved standard. Document M27-A. National Committee for Clinical and Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(95)00010-0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411173312001"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/313749"},{"key":"e_1_3_2_21_2","unstructured":"Sanglard D. F. Ischer O. Marchetti J. Entenza and J. Bille. Calcineurin A of Candida albicans : involvement in antifungal tolerance cell morphogenesis and virulence. Mol. Microbiol. in press."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2300"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2378"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1859"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.1990.tb02650.x","volume":"75","year":"1990","unstructured":"Sonneveld, P., and K. Nooter. 1990. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukemia. Br. J. Haematol.75:208-211.","journal-title":"Br. J. Haematol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690507"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/313498"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.12.2481"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.5.1565-1570.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.5.1565-1570.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:12:08Z","timestamp":1645467128000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.5.1565-1570.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1128\/AAC.47.5.1565-1570.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.5.1565-1570.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]},"assertion":[{"value":"2002-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}